pp-114 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
Indication: Chronic spontaneous urticaria (CSU) in patients with persistent hives and pruritus inadequately controlled by antihistamines
Clinical stage: Phase II clinical development in Japan
Modality: Small molecule
Mechanism / Target: MRGPRX2 (Mas‑related G‑protein coupled receptor X2) antagonist to reduce mast‑cell mediated itch and wheal formation
Route / form: Oral formulation
Differentiation: Targets a novel itch‑related receptor (MRGPRX2) offering potential benefit for patients refractory to standard antihistamine therapies, representing a targeted small molecule approach in dermatologic immunomodulation
Manufacturer #492
Leading clinical‑stage dermatology pharma with broad R&D, manufacturing and commercialization focus on skin diseases, expanding into metabolic and specialty areas. It pursues strategic collaborations and global development through regional subsidiaries and innovation partnerships. The organization emphasises quality, regulatory compliance and expanding patient‑centric solutions.